John Micek - 24 Jun 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Reporting relationship: Director
Issuer ticker: JAGX
Reported as of: 24 Jun 2025
Net transaction value: +$23,100,000
SEC form: 4
Accepted by SEC: 26 Jun 2025, 16:40:04 UTC
Prior SEC filing: 02 Apr 2025
Next SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John Micek

Key filing fact

John Micek filed Form 4 for Jaguar Health, Inc. (JAGX) on 26 Jun 2025.

Key facts

This page summarizes John Micek's Form 4 filing for Jaguar Health, Inc. (JAGX).
3 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 26 Jun 2025, 16:40.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: +$23,100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001243187 Primary reporting owner

MICEK JOHN

Relationship: Director
Address: C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO
Signature: /s/ John Micek
Signature date: 26 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JAGX transaction Derivative

Convertible Promissory Note

Disposed to Issuer

Transaction value: $450,000,000
Shares: -9,000
Change %: -100%
Price: $50000.00
Shares after: 0
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,000
Exercise price: $5.56
Footnotes: F1

JAGX transaction Derivative

Convertible Promissory Note

Award

Transaction value: $473,100,000
Shares: +9,462
Change %
Price: $50000.00
Shares after: 9,462
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,462
Exercise price: $5.56
Footnotes: F1

JAGX transaction Derivative

Warrant to Purchase Common Stock

Award

Transaction value
Shares: +18,262
Change %
Price
Shares after: 9,000
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,262
Exercise price: $2.70
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person disposed of a 6% convertible promissory note maturing on 6/30/2025 (the "Original Note") that was originally issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 in exchange for a new 6% convertible promissory note that matures on 1/30/2026 (the "New Note") in an issuer exchange offer. The New Note is convertible, at the reporting person's option, in part or in full, into an aggregate of 9,462 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.

Footnote F2

As an inducement to enter into the issuer exchange offer, the reporting person received a warrant (the "Warrant") to purchase up to 18,262 shares of Common Stock with an exercise price of $2.70 per share. The Warrant is exercisable immediately upon receipt of stockholder approval and will expire on the earlier of (i) 18 months from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.